CCO Independent Conference Coverage

Faculty:
	David A. Cooper, MD, DSc Joel E. Gallant, MD, MPH Kimberly Y. Smith, MD, MPH

Resistance and Management of Treatment-Experienced Patients

Track 2 of 6

Faculty:
	W. David Hardy, MD Kathleen E. Squires, MD Andrew R. Zolopa, MD

Investigational Antiretrovirals

Track 3 of 6

Faculty:
	Joseph J. Eron, Jr., MD Daniel R. Kuritzkes, MD William G. Powderly, MD

Current Issues in Antiretroviral Therapy

Track 4 of 6

Faculty:
	Pedro Cahn, MD, PhD Roy M. Gulick, MD, MPH Joep MA Lange, MD, PhD

Metabolic Complications and Adverse Events

Track 5 of 6

Faculty:
	Judith S. Currier, MD, MSc Sally Hodder, MD Donald P. Kotler, MD

Hepatitis and Opportunistic Diseases

Track 6 of 6

Faculty:
	Richard E. Chaisson, MD Bruce Polsky, MD Jürgen K. Rockstroh, MD

CME-Certified Slideset

Review and download slides summarizing the most clinically relevant data on antiretroviral therapy and complications of HIV disease at the recent Retrovirus meeting Los Angeles.

This slide presentation is in Microsoft PowerPoint format and is available for download within the CME module.

Metabolic Complications: Update From Los Angeles

Faculty:
Judith S. Currier, MD, MSc Joseph J. Eron, Jr., MD Joel E. Gallant, MD, MPH
Sally Hodder, MD Donald P. Kotler, MD William G. Powderly, MD
Kimberly Y. Smith, MD, MPH Andrew R. Zolopa, MD

CME CREDIT INFORMATION

Release Date: 04/05/07

Expiration Date: 04/04/08

Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Distinguished faculty review the most clinically relevant new data from the Retrovirus meetings in Los Angeles, February 2007.

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe observations about the natural history of HIV infection and the development of metabolic complications
Specify data on metabolic complications observed in recent studies of approved and investigational antiretroviral agents
Discuss recent insights into the management and prevention of metabolic complications in HIV-infected patients

CCO Slideset – Metabolic Complications: Update From Los Angeles

Format: Microsoft PowerPoint (.ppt) | File size: 513 KB

Expert Highlights (mp3)

Listen to the experts summarize the most important data from the Los Angeles meeting with our exclusive CCO Podcasts!

These audio files are in mp3 format. To listen to the audio, simply click "Download Audio." You must be logged onto the clinicaloptions.com site to listen to or download the mp3 files.

Joseph J. Eron, Jr, MD, notes that there were very few reports on drugs in early clinical development at this meeting and discusses the implications of that for treatment of highly experienced patients.
(3 minutes)

Judith S. Currier, MD, MSc, reviews data from 2 antiretroviral clinical studies that provide information on strategies to decrease treatment-related lipoatrophy in HIV-infected patients. (4 minutes)

Bruce Polsky, MD, reviews key presentations on the management of coinfections in HIV-infected patients including TB-related testing, morbidity and mortality, impact of unsafe sexual practices on acute HCV infection in men who have sex with men, and surprising results that may impact the use of entecavir for the treatment of HBV/HIV-coinfected patients. (10 minutes)

W. David Hardy, MD, discusses the results of phase 3 studies of raltegravir (MK-0518) and maraviroc in triple-class-experienced patients, and highlights the availability of these agents, as well as etravirine, through expanded access programs. (3 minutes)

Joel Gallant, MD, MPH, discusses the phase IIb comparison of TMC278, a second generation NNRTI, with efavirenz in antiretroviral-naive patients and notes that this agent may challenge efavirenz in this arena. (3 minutes)